drugset
drugset / Trial / NCT05032144

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

NCT05032144 ↗

Phase 1 Completed 40 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized,double-blind,placebo-controlled,single-ascending dose phase Ⅰa study to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

Timeline

Start
2021-09-28
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GREZIPRUBART Monoclonal antibody 2 mg/kg Intravenous
Subject GREZIPRUBART Monoclonal antibody 5 mg/kg Intravenous
Subject GREZIPRUBART Monoclonal antibody 10 mg/kg Intravenous
Subject GREZIPRUBART Monoclonal antibody 20 mg/kg Intravenous
Subject GREZIPRUBART Monoclonal antibody 30 mg/kg Intravenous

Indications

No indication recorded.